Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection

PURPOSE: To characterize amatuximab pharmacokinetics (PK) and the relationship of amatuximab exposure with response in patients with unresectable malignant pleural mesothelioma (MPM) receiving amatuximab with pemetrexed and cisplatin. METHODS: A nonlinear mixed effects PK model was built using data...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Gupta, Anubha, Hussein, Ziad, Hassan, Raffit, Wustner, Jason, Maltzman, Julia D., Wallin, Bruce A.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202971/
https://ncbi.nlm.nih.gov/pubmed/26898299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-2984-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars